Le Lézard
Classified in: Science and technology, Covid-19 virus
Subject: OBI

VerifyMe Announces Passing of Company Founder and Former Chairman Norman Gardner


ROCHESTER, N.Y., Feb. 18, 2022 /PRNewswire/ -- VerifyMe, Inc. (NASDAQ: VRME) ("VerifyMe," "we," "our," or the "Company"), announced today that Norman Gardner, former Chairman and founder of VerifyMe, has passed away due to complications from COVID-19. 

It is with great sadness that VerifyMe announces the passing of our founder, Norman Gardner.  Mr. Gardner was previously a director and Vice-Chairman of the Company from the Company's inception in November 1999 until January 2013.  He served as our Chief Executive Officer from November 1999 until January 2013, and from January 2017 until August 2017.  Mr. Gardner was the Chairman of the Board from June of 2017 until April of 2021. He has been a consultant to the Company since his departure as Chairman.

Patrick White, Chief Executive Officer commented, "Norm's sudden passing is a tremendous loss.  Norman was not only our founder he was also a brilliant inventor who worked every day over the last 20 plus years to improve and nurture VerifyMe.  On a personal note, Norman was my mentor and one of my very best friends.  We will miss him immensely.   We extend our sympathies to his family, particularly his wife, Annette." 

About VerifyMe, Inc.
VerifyMe, Inc. (NASDAQ: VRME), is a technology solutions provider specializing in products to connect brands with consumers. VerifyMe technologies give brand owners the ability to gather business intelligence while engaging directly with their consumers. VerifyMe technologies also provide brand protection and supply chain functions such as counterfeit prevention, authentication, serialization, and track and trace features for labels, packaging and products. To learn more, visit www.verifyme.com.

SOURCE VerifyMe, Inc.


These press releases may also interest you

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 17:15
Amgen and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood...

18 mai 2024
Emmy-winning actor and St. Louis native Jon Hamm took the stage Saturday, May 18, to offer words of wisdom to the newest graduates of Saint Louis University (SLU) during the University's spring commencement in St. Louis. ...

18 mai 2024
Nearly 900 undergraduates of the Class of 2024 celebrated their send-off from Bentley University in a very different way than their 2020 arrival amid the COVID-19 pandemic. The 105th undergraduate commencement ceremony was marked by maskless smiles,...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: